# A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus

> **NCT06955598** · PHASE1 · COMPLETED · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 30 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** SHR-2173

## Key facts

- **NCT ID:** NCT06955598
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-24
- **Primary completion:** 2025-11-10
- **Final completion:** 2025-11-21
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06955598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06955598, "A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06955598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*